| Identification | Back Directory | [Name]
1,3,5-Triazine-2,4-diamine, N2-(4-bromophenyl)-3,6-dihydro-6,6-dimethyl- | [CAS]
393129-91-4 | [Synonyms]
WAY-388264-A
1,3,5-Triazine-2,4-diamine, N2-(4-bromophenyl)-3,6-dihydro-6,6-dimethyl- | [Molecular Formula]
C11H14BrN5 | [MOL File]
393129-91-4.mol | [Molecular Weight]
296.17 |
| Chemical Properties | Back Directory | [Melting point ]
137 °C | [Boiling point ]
382.0±44.0 °C(Predicted) | [density ]
1.60±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
9.96±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC50 value of 33.4 nM. 5-HT2B antagonist-1 can be used in studies of diseases characterized by 5-HT2B receptor signaling, such as hepatocellular carcinoma, cardiovascular disease or gastrointestinal disease[1][2]. | [Biological Activity]
5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC50 value of 33.4 nM. 5-HT2B antagonist-1 can be used in studies of diseases characterized by 5-HT2B receptor signaling, such as hepatocellular carcinoma, cardiovascular disease or gastrointestinal disease[1][2].
5-HT2B antagonist-1 (compound 5g) has some sodium channel binding activity with IC50 values in the range of 12.6 to 57.5 μM[1].5-HT2B antagonist-1 (coumpound 1-e) inhibits 5-HT2B receptor activity by less than 50% at 1 μM in CHO-K1 cell lines[3].
5-HT2B antagonist-1 (compound 15) (oral gavage, 30 mg/kg) can reduce visceral hypersensitivity significantly in irritable bowel syndrome (IBS) rats[2]. | [in vivo]
5-HT2B antagonist-1 (compound 15) (oral gavage, 30 mg/kg) can reduce visceral hypersensitivity significantly in irritable bowel syndrome (IBS) rats[2]. | [IC 50]
5-HT2B Receptor: 33.4 nM (IC50) | [References]
[1]. Xiang Ma, et al. Synthesis and in vitro evaluation of 2,4-diamino-1,3,5-triazine derivatives as neuronal voltage-gated sodium channel blockers. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5644[2]. Yu Zhou, et al. Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome. J Med Chem. 2016 Jan 28;59(2):707-20.[3]. Huang Niu, et al. 5-HT2B Antagonists. WO2015158214 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|